Improving treatment for glioblastoma by targeting how cancer cells use nutrients
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma
This study is looking at how glioblastoma cells survive radiation treatment and testing a medication called mycophenolate mofetil (MMF) to see if it can help make radiation therapy more effective for patients with this type of brain cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11081658 on NIH RePORTER |
What this research studies
This research investigates how glioblastoma cells, which are known for their aggressive nature and resistance to treatments, utilize nucleotide metabolism to survive and resist radiation therapy. The study aims to understand the relationship between radiation response and purine synthesis in these cancer cells. By using a drug called mycophenolate mofetil (MMF), which inhibits purine synthesis, the researchers will explore its effectiveness in enhancing the impact of radiation therapy. A clinical trial will be conducted to find the optimal dose of MMF that can be safely administered alongside radiation to improve treatment outcomes for patients with glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing radiation therapy.
Not a fit: Patients with glioblastoma who are not receiving radiation therapy or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment options for patients with glioblastoma.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer treatment, indicating potential for success with this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wahl, Daniel R — University of Michigan at Ann Arbor
- Study coordinator: Wahl, Daniel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.